Barclays PLC Acquires 100,498 Shares of Wave Life Sciences Ltd. (NASDAQ:WVE)

Barclays PLC increased its stake in Wave Life Sciences Ltd. (NASDAQ:WVE) by 171.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 159,241 shares of the company’s stock after buying an additional 100,498 shares during the quarter. Barclays PLC owned about 0.13% of Wave Life Sciences worth $1,307,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in WVE. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Wave Life Sciences by 23.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,512 shares of the company’s stock valued at $37,000 after acquiring an additional 856 shares during the period. Profund Advisors LLC bought a new stake in shares of Wave Life Sciences during the second quarter worth $53,000. Principal Financial Group Inc. purchased a new stake in shares of Wave Life Sciences during the second quarter valued at $74,000. Mackenzie Financial Corp grew its holdings in shares of Wave Life Sciences by 13.6% in the second quarter. Mackenzie Financial Corp now owns 15,887 shares of the company’s stock worth $79,000 after purchasing an additional 1,905 shares during the last quarter. Finally, Point72 DIFC Ltd purchased a new position in Wave Life Sciences in the 3rd quarter worth about $98,000. 89.73% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other Wave Life Sciences news, CEO Paul Bolno sold 90,474 shares of the company’s stock in a transaction dated Wednesday, October 16th. The shares were sold at an average price of $15.00, for a total value of $1,357,110.00. Following the completion of the transaction, the chief executive officer now owns 268,585 shares in the company, valued at approximately $4,028,775. This represents a 25.20 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Chris Francis sold 36,000 shares of Wave Life Sciences stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $16.00, for a total value of $576,000.00. The disclosure for this sale can be found here. Insiders sold a total of 436,544 shares of company stock valued at $6,271,569 in the last quarter. 29.10% of the stock is currently owned by company insiders.

Wave Life Sciences Trading Down 4.3 %

Shares of NASDAQ WVE opened at $12.90 on Friday. The company has a 50 day simple moving average of $14.41 and a two-hundred day simple moving average of $9.25. The stock has a market cap of $1.97 billion, a price-to-earnings ratio of -11.62 and a beta of -1.21. Wave Life Sciences Ltd. has a 12 month low of $3.50 and a 12 month high of $16.74.

Analyst Upgrades and Downgrades

WVE has been the subject of a number of research analyst reports. Wells Fargo & Company lifted their target price on Wave Life Sciences from $11.00 to $22.00 and gave the company an “overweight” rating in a research report on Wednesday, October 16th. Leerink Partners lifted their price objective on Wave Life Sciences from $20.00 to $22.00 and gave the company an “outperform” rating in a report on Wednesday, October 16th. HC Wainwright reiterated a “buy” rating and set a $22.00 target price on shares of Wave Life Sciences in a report on Wednesday, November 13th. Royal Bank of Canada raised their target price on shares of Wave Life Sciences from $7.00 to $15.00 and gave the company a “sector perform” rating in a research report on Monday, October 21st. Finally, Truist Financial upped their price target on shares of Wave Life Sciences from $17.00 to $36.00 and gave the stock a “buy” rating in a research report on Tuesday, November 12th. One analyst has rated the stock with a sell rating, one has given a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $22.22.

About Wave Life Sciences

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.